Policy & Compliance

  • May 28, 2026

    9th Circ. Won't Revisit FCA Ruling Over Drug Price Program

    The Ninth Circuit has said it will not disturb its March ruling allowing a hospital chain to pursue a False Claims Act lawsuit against various pharmaceutical companies for allegedly causing the government to overpay for drugs under a discount program.

  • May 27, 2026

    Pharmacies Beat Fla. Hospitals' Opioids Suit

    A Florida state judge has handed Walmart, Walgreens and CVS a win in a fight with hospitals over treatment of opioid-addicted patients, finding the hospitals cannot recover damages under state racketeering law because their injuries are indirect.

  • May 27, 2026

    ProPublica Denied Access To Ranbaxy Antitrust MDL Docs

    A Massachusetts federal court denied ProPublica's bid to unseal court filings in settled multidistrict litigation alleging a subsidiary of Indian drugmaker Sun Pharmaceuticals illegally delayed market entry of generic drugs, ruling the nonprofit news organization's request came too late in the case.

  • May 27, 2026

    Judge Doubts Prison Bureau Claim Trans Care Isn't Banned

    A D.C. federal judge repeatedly challenged a Trump administration attorney's claims that a looming ban on gender-affirming care in federal prisons wouldn't amount to a categorical ban on hormone treatments for inmates as he weighed extending an injunction already stopping the policy from taking effect.

  • May 27, 2026

    NY-Presbyterian Says DOJ's Antitrust Case Is Misguided

    New York-Presbyterian Hospital is pushing back against claims that it blocks cheaper insurance plans through its contracts with insurers, telling a federal court that enforcers are challenging industry-standard contract terms that lower prices and guarantee patient access.

  • May 27, 2026

    US Tells Justices To Hold 'Lightning Rod' Health Ministry Case

    The U.S. Supreme Court should hold out on deciding whether a New Mexico insurance law violates the religious rights of nonprofit healthcare-sharing ministries that provide cheap, Christian-focused health insurance options while the justices decide a similar case, the U.S. solicitor general told the court. 

  • May 26, 2026

    9th Circ. Won't Revive Wash. City Workers' Vax Mandate Suit

    A Ninth Circuit panel Tuesday put an end to city workers' lawsuit challenging Bellingham, Washington's COVID-19 vaccine mandate, ruling that a lower court appropriately dismissed the action and barred the workers from amending their claims.

  • May 26, 2026

    Seattle Hospital Loses Appeal Of Dr.'s $21M Race Bias Verdict

    A Washington Court of Appeals panel Tuesday upheld a $21 million verdict against Seattle Children's Hospital in a Black ex-medical director's lawsuit claiming he faced racism in the workplace and retaliation for complaining about systemic inequities, ruling "substantial evidence" justified the jury's findings and damages award.

  • May 26, 2026

    New Suits Target DOJ Release, Loan Rule And More

    Law360 Healthcare Authority looks at new suits filed over the past week, including a $50 million suit over the U.S. Justice Department's handling of a criminal case against Maryland doctors and another challenge over the U.S. Department of Education's rule altering federal student loan eligibility.

  • May 26, 2026

    Meet The Attys For Health Orgs. Fighting Ed. Dept. Loan Caps

    A group of healthcare organizations has tapped a new law firm founded by a former Biden administration attorney to challenge a U.S. Department of Education rule that restricts student loan eligibility for some degree programs. 

  • May 26, 2026

    6th Circ. Rejects Mich. Reproductive Rights Challenge

    Abortion opponents and several parents lack standing to sue top Michigan officials, the Sixth Circuit said Tuesday, affirming dismissal of a suit challenging the state's voter approved reproductive rights amendment.

  • May 26, 2026

    9th Circ. Backs Reinstating DEI Grants Nixed By Trump

    The Ninth Circuit on Tuesday partially upheld a lower court's preliminary injunction and class certification orders in litigation from University of California researchers against President Donald Trump, backing the reinstatement of grants terminated due to presidential orders against diversity, equity and inclusion initiatives while reversing the injunction for those grants that were rescinded without explanation.

  • May 26, 2026

    Conn. Drug Price Law Still Allows Hikes, 2nd Circ. Told

    Wholesale distributors that abide by Connecticut's drug price cap law can hike the cost of their other products to ensure they don't suffer losses, the state told the Second Circuit Tuesday, raising the ire of the companies trying to invalidate the new statute.

  • May 26, 2026

    DOJ Escalates Gender Care Probes With Criminal Subpoenas

    Facing mounting court losses in challenges to civil subpoenas, justice officials escalated the Trump administration's opposition to gender care providers with a grand jury's criminal subpoena.

  • May 26, 2026

    Squires' Institution Flips Are Increasing Uncertainty At PTAB

    U.S. Patent and Trademark Office Director John Squires has created a record low institution rate at the Patent Trial and Appeal Board, and attorneys say it's becoming increasingly clear that even an initial approval from the director may not last.

  • May 26, 2026

    Judge Tosses Anti-Pot Suit Over CMS Hemp Benefits Program

    A D.C. federal judge has thrown out a challenge to a Centers for Medicare & Medicaid Services program to give Medicare beneficiaries access to federally legal hemp products, finding none of the groups or individuals who aimed to block the program have standing.

  • May 22, 2026

    Law360 Reveals Titans Of The Plaintiffs Bar

    This past year, 10 lawyers across the country at plaintiffs' firms big and small helped secure millions of dollars in settlements and verdicts for their clients, going up against powerful defendants like Google, Monsanto and the Trump administration, earning the attorneys recognition as Law360's Titans of the Plaintiffs Bar for 2026.

  • May 22, 2026

    Healthcare Orgs Push DC Court To Block Student Loan Caps

    Professional organizations representing nurses, therapists, public health workers and educators urged a District of Columbia federal court on Thursday to block a rule by the U.S. Department of Education restricting federal student loan eligibility for a host of degree programs, arguing it exceeded the department's authority.

  • May 22, 2026

    Hospital Pulls $1M Medicare Suit Against UnitedHealthcare

    A Connecticut hospital has dropped a lawsuit alleging UnitedHealthcare owed it more than $1 million after refusing to correct errors in Medicare Advantage cost calculations, state court records show.

  • May 22, 2026

    Trump's Melding Of Politics, Antitrust Hard To Roll Back

    Environmental initiatives, diversity programs, anti-misinformation efforts and gender-affirming care have become central targets for President Donald Trump's antitrust enforcers in what observers say is an increasing trend of politically tinged competition enforcement.

  • May 21, 2026

    PBM Swaps Cravath For WilmerHale In Price-Fixing Suit

    Pharmacy benefit manager Prime Therapeutics LLC has replaced counsel Cravath Swaine & Moore LLP with WilmerHale and another firm in an antitrust case in Michigan federal court brought by the state's attorney general.

  • May 21, 2026

    9th Circ. Told To Reject J&J Unit's $442M Antitrust Appeal

    Cardiac catheter refurbisher Innovative Health urged the Ninth Circuit to reject the appeal from Johnson & Johnson's Biosense Webster unit seeking to upend its $442 million antitrust judgment, saying the lower court rightly found that Biosense forced hospitals to avoid refurbished catheters in favor of its own.

  • May 21, 2026

    FTC's Gender Care Policy Might Not Sink Probe, Judge Says

    A D.C. federal judge wondered Thursday whether it would set a bad precedent for future commissions to label the Federal Trade Commission's investigative demand to the American Academy of Pediatrics as "retaliatory" just because agency officials have issued a policy statement attacking gender-affirming care for minors.

  • May 21, 2026

    Medical Practice Calls $49M Missed Cancer Verdict 'Unjust'

    The Westchester Medical Group PC has asked a Connecticut state judge to find most of a $49 million jury verdict "excessive, unjust, and entirely disproportionate" to claims its staff repeatedly failed to diagnose cancer despite multiple warning signs, calling the award punitive and not supported by the evidence.

  • May 20, 2026

    2nd Circ. Skeptical Of Bid To Boost Drug Royalty Award

    A Second Circuit panel appeared unsympathetic during oral arguments on Wednesday to Acorda Therapeutics Inc.'s assertion that it should be awarded nearly $66 million beyond the $16.5 million it won in a multiple sclerosis drug dispute, with one judge remarking that the company is "kind of in the soup" because it chose arbitration.

Expert Analysis

  • A Rapidly Evolving Landscape For Noncompetes In Healthcare

    Author Photo

    A wave of new state laws regulating noncompete agreements in the healthcare sector, varying in scope, approach and enforceability, are shaped by several factors unique to the industry and are likely to distort the market, say attorneys at Seyfarth.

  • Arguing The 8th Amendment For Reduction In FCA Penalties

    Author Photo

    While False Claims Act decisions lack consistency in how high the judgment-to-damages ratio in such cases can be before it becomes unconstitutional, defense counsel should cite the Eighth Amendment's excessive fines clause in pre-trial settlement negotiations, and seek penalty decreases in post-judgment motions and on appeal, says Scott Grubman at Chilivis Grubman.

  • $95M Caremark Verdict Should Put PBMs On Notice

    Author Photo

    A Pennsylvania federal judge’s recent ruling that pharmacy benefits manager CVS Caremark owes the government $95 million for overbilling Medicare Part D-sponsored drugs highlights the effectiveness of the False Claims Act, as scrutiny of PBMs’ outsized role in setting drug prices continues to increase, say attorneys at Duane Morris.

  • DOJ Actions Signal Rising Enforcement Risk For Health Cos.

    Author Photo

    The U.S. Department of Justice's announcement of a new False Claims Act working group, together with the largest healthcare fraud takedown in history, underscore the importance of sophisticated compliance programs that align with the DOJ's data-driven approach, say attorneys at Debevoise.

  • Spotlight On Medicare Marketing Practices Enforcement Trend

    Author Photo

    Recent U.S. Department of Justice actions, including its recent Medicare kickback allegations in Shea v. eHealth, demonstrate increasing enforcement scrutiny on Medicare Advantage marketing practices, say Ellen London at London & Naor, Li Yu at Bernstein Litowitz and Erica Hitchings at the Whistleblower Law Collaborative.

  • Federal Regs Order May Spell Harsher FDCA Enforcement

    Author Photo

    A recent executive order aimed at reducing criminal prosecutions of those who unknowingly violate complex federal regulations may actually lead to more aggressive felony indictments under the Federal Food, Drug and Cosmetic Act, but companies and executives can mitigate risks by following several key principals, say attorneys at McGuireWoods.

  • What High Court's Tenn. Trans Care Ruling Means Nationally

    Author Photo

    The U.S. Supreme Court's decision in U.S. v. Skrmetti, upholding a Tennessee ban on gender-affirming medical care for minors, is fairly limited in scope and closely tailored to the specific language of Tennessee's law, but it may have implications for challenges to similar laws in other states, say attorneys at Hall Render.

  • High Court ACA Ruling May Harm Preventative Care

    Author Photo

    The U.S. Supreme Court's decision in Kennedy v. Braidwood last week, ruling that the U.S. Department of Health and Human Services secretary has authority over an Affordable Care Act preventive care task force, risks harming the credibility of the task force and could open the door to politicians dictating clinical recommendations, says Michael Kolber at Manatt.

  • Rising Enforcement Stakes For Pharma Telehealth Platforms

    Author Photo

    Two pieces of legislation recently introduced in Congress could transform the structure and promotion of telehealth arrangements as legislators increasingly scrutinize direct-to-consumer advertising platforms, potentially paving the way for a new U.S. Food and Drug Administration policy with bipartisan support, say attorneys at Sheppard Mullin.

  • 3 Judicial Approaches To Applying Loper Bright, 1 Year Later

    Author Photo

    In the year since the U.S. Supreme Court overturned Chevron deference in its Loper Bright Enterprises v. Raimondo decision, a few patterns have emerged in lower courts’ application of the precedent to determine whether agency actions are lawful, say attorneys at Husch Blackwell.

  • How Providers Can Brace For Drug Pricing Policy Changes

    Author Photo

    Though it's uncertain which provisions of the Trump administration's executive order aimed at addressing prescription drug costs will eventually be implemented, stakeholders can reduce potential negative outcomes by understanding pathways that could be used to effectuate the order's directives, say attorneys at McDermott.

  • Debunking 4 Misconceptions Around Texas' IV Therapy Law

    Author Photo

    Despite industry confusion, an IV therapy law enacted in Texas last week may actually be the most business-friendly regulatory development the medical spa industry has seen in recent years, says Keith Lefkowitz at Hendershot Cowart.

  • Legacy Of 3 Justices Should Guide Transgender Rights Ruling

    Author Photo

    Three Republican-appointed U.S. Supreme Court justices — Anthony Kennedy, Sandra Day O'Connor and David Souter — gave rise to a jurisprudence of personal liberty that courts today invoke to protect gender-affirming care, and with the court now poised to decide U.S. v. Skrmetti, it must follow the path that they set, says Greg Fosheim at McDermott.